Transformez ce poste en entretien — un CV et une lettre de motivation conçus selon ce que cet employeur recherche.
KU Leuven invites applications for a 4-year PhD on AI-driven multimodal data fusion models in rare diseases, hosted in the Department of Human Genetics, Leuven, Belgium. The successful candidate will work under Prof.
Alejandro Sifrim with international co-supervisors. You will develop zero-shot multimodal fusion models using spatial and single-cell omics, histopathology, and clinical data to enable diagnostic prediction, with secondments at University of Manchester and Spotlight Pathology Ltd.
KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.
Host institution: KU Leuven, Department of Human Genetics, Leuven, Belgium
Supervisor: Prof. Alejandro Sifrim (KU Leuven, Belgium)
Co-supervisors: Dr. Martin Fergie, University of Manchester, United Kingdom (academic partner); Dr. Samantha Perona, Spotlight Pathology Ltd., United Kingdom (industry partner)
Host laboratory:
The PhD fellow will be based at KU Leuven, in the group of Prof. Alejandro Sifrim. The laboratory specialises in computational biology, artificial intelligence and statistical modelling for the integration of single-cell and spatial multi-omics data. KU Leuven offers a highly interdisciplinary environment, with expertise spanning computational biology, spatial omics and precision medicine.
The host laboratory provides access to advanced computational infrastructure, including GPU- and CPU-based high-performance compute servers and large-scale storage for multimodal data analysis. Through LISCO (Leuven Institute for Single-cell Omics), the candidate will also have access to state-of-the‑art single-cell and spatial multi-omics technologies, imaging platforms and integrated bioinformatics resources.
The candidate will develop and benchmark zero‑shot multimodal fusion models for rare disease prediction, using melanoma as a use case. The project integrates spatial and single‑cell multi‑omics data with histopathology and clinical information to learn robust cross‑modal representations for diagnostic prediction. It pursues two integrated objectives: (i) to develop generative and explainable AI approaches for multimodal data fusion; and (ii) to extend existing multimodal frameworks with additional omics layers and evaluate their performance across heterogeneous datasets. At KU Leuven, the candidate will develop machine‑learning strategies for multimodal representation learning and for the integration of the complex biological datasets generated within the consortium.
Duration and start date: 48 months, full‑time. The first 36 months are funded by the MSCA Doctoral Network SPACE-MEL; the appointment is extended to a full four‑year doctoral trajectory at KU Leuven. Intended start date: begin 2027.
Eligibility conditions:
Required skills:
Secondments:
The doctoral candidate will receive a competitive salaryin accordance with the MSCA Doctoral Networks program, comprising a living allowance and a mobility allowance. A family allowance is foreseen where applicable.
KU Leuven additionally offers holiday pay, hospitalization insurance, reimbursement of certain commuting costs and access to its sports and childcare facilities.
KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.
Title
PhD on AI-driven multimodal data fusion models in rare diseases
2026-10-15 23:59 (Europe/Brussels)
2026-10-15 23:59 (CET)
Closing on: 2026-10-02 (Europe/Brussels)
Closing on: 2026-09-30 (Europe/Brussels)
Closing on: 2026-10-15 (Europe/Brussels)
Closing on: 2026-10-16 (Europe/Brussels)
Closing on: 2026-10-30 (Europe/Brussels)